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Drug treatmentDiabetic nephropathy (DN) is a serious complication of longstanding diabetes affecting up to 30% of all diabetes
patients and is the main cause of end-stage kidney disease globally. Current standard treatment e.g. ACE-inhibitors
like enalapril merely offers a delay in the progression leading to DN. Herein, we describe in two preclinical models
evidence to local effects on the inﬂammatory signatures after intervention treatment with enalapril which provides
enhanced understanding of the mechanism of ACE inhibitors.
Enalapril transiently reduced albuminuria in both the db/db and the STZ-induced DN models with established
disease, without modulating the HbA1c%. Albuminuria was strongly associated with loss of leukocytes, particularly
B cells, but also of sub-populations of macrophages and CD4+ T cells. The remaining kidney macrophages were
polarized into a M2-like sub-population with reduced surface expression of the M1-like macrophage marker
CD11c and enhanced expression of galectin-3. Enalapril treatment counteracted the reduction of leukocytes in the
diabetic kidney towards levels noted in the non-diabetic kidney. Particularly, a subset ofmacrophageswas increased
and a clear expansion of CD4+ and CD8+ T cells was observed. However, enalapril failed to modulate the B cell
compartment. Interestingly, enalapril treatment resulted in a re-polarization of the macrophages towards a
M1-like phenotype characterized by elevated levels of CD11cwithmoderate down-regulation of theM2marker
galectin-3.
The data demonstrate that ACE inhibition in pre-clinical models of DN shows a transient beneﬁcial effect on
albuminuriawhich is unexpectedly associatedwith restoration of T cells andM1-likemacrophages in the kidney.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic nephropathy (DN) is a serious complicationof type2diabetes
(T2D)with a prevalence of 30% of all diabetes patients [1]. DN is themain
kidney disease leading to end stage renal disease (ESRD) and hence
requirement for transplantations worldwide [1]. The disease is
characterized bymorphological and ultrastructural changes in the kidney
including glomerular basement membrane thickening, mesangial expan-
sion, nodular increase inmesangial matrix, glomerulosclerosis and ﬁnally
interstitial ﬁbrosis [2]. These modulations in the kidney tissue disrupt the
ﬁltration barrier, which lead to marked increase of albumin in the urine
(albuminuria) and cause a decline in glomerular ﬁltration rate (GFR)
[2]. First line therapy in DN patients is angiotensin converting enzyme
(ACE) inhibitors like enalapril [3]. These agents are thought to work
mainly by lowering global and local blood pressure thereby reducing
the pressure on the kidney. However, enalapril does have additional
unclear kidney protective properties in addition to blood pressuregy, Novo Nordisk Park, DK-2720
l).
. This is an open access article undermodulation as other blood pressure reagents with higher efﬁcacy
fail to protect the kidney from development of albuminuria [4].
Angiotensin II is known to have pro-inﬂammatory properties and
thus additional beneﬁcial effect of enalapril might be due to a reduction
of inﬂammation [5].
Emerging evidence suggests inﬂammation to play essential roles in
the pathogenesis of T2D and diabetic complications including DN
[6–13]. Inﬁltrating macrophages have been found in both diabetic
kidneys from experimental animal models and human DN renal biopsies
[12–14]. In human DN, macrophages and T cells accumulate in the
glomeruli and interstitium, even in the early stages of the disease when
the patient only showsminimal clinical symptoms [10,11]. These recruit-
ed inﬂammatory cells secrete pro-inﬂammatory cytokines in the renal en-
vironment triggering the release of a spectrum of chemokines along with
the increased expression of adhesion molecules on resident renal cells
[15]. This local inﬂammatory milieu further ampliﬁes the migration of
leukocytes initiating signaling cascades in the kidney tissue leading to
detrimental effector functions considered to contribute to the clinical
symptoms.
Macrophages are a heterogeneous population of cells. They express
various levels ofmacrophagemarkers such as F4/80 andCD68, dependingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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environment provides macrophages with various stimuli creating an
array of tissue speciﬁc distinct cells. The macrophages activated by
inﬂammatory stimuli such as IFN-γ, LPS, and TNF-α, polarize towards
a classical M1-like phenotype, contributing with pro-inﬂammatory
cytokines such as IL-12 and IFN-γ [18]. The alternatively activated
M2-like phenotype, induced by Th2 cytokines such as IL-4 and IL-13
as well as galectin-3, contributes with IL-4, IL-10 and TGF-β production
to tissue repair and remodeling in the resolution of an inﬂammatory
response [19,20]. However, under certain conditions with unresolved
chronic inﬂammation, an excessive activation of the M2 macrophages
initiates pathological wound healing processes, resulting in irreversible
ﬁbrosis, tissue destruction and progressive chronic disease [21]. Recently,
we described that in the db/db model of T2D, the local islet invading
macrophages displays a M1-like phenotype in early disease, which was
in the chronic stage of T2D re-polarized towards a M2-like phenotype
also in the systemic compartment [22].
Macrophages account for the majority of leukocytes found in the
kidney in DN and are believed to be central players in the DN pathogen-
esis [12,23]. Recently, several studies have investigated the state of acti-
vation and the phenotype of macrophages in the nephrotic kidney
showing considerable phenotypic changes during disease progression.
Macrophages inﬁltrating the kidney in early ﬁbrotic kidney disease are
predominantly of the M1 pro-inﬂammatory phenotype contributing to
renal injury [24–26]. These macrophages subsequently undergo a local
shift towards M2 macrophages which are the predominate phenotype
during the recovery and repair phase and are suggested to be the
main players responsible for subsequent development of ﬁbrosis at
the later stage of the disease [25]. Recently, a study by Fujiu et al.
conﬁrmed the previous ﬁndings by identifying two distinctmacrophage
subsets based on the expression of CD11b and F4/80 with different
gene expression proﬁles and mutually exclusive functions [27]. The
CD11b+F480low subset accumulated at an early time point inducing
apoptosis and tissuedestructionwhereas theCD11b+F480himacrophage
subset increased at a later stage and was responsible for tissue
remodeling and ﬁbrosis [27].
Galectin-3 (the Mac-2 antigen), a β-galactoside-binding soluble
lectin is highly expressed on activated macrophages and is well
known for its immunoregulatory functions [28,29]. Galectin-3 positive
macrophages are increased in the systemic splenic compartment in the
db/db T2D model at the age when signiﬁcantly enhanced albuminuria
and mesangial cell expansion resembling DN are present [22,30].
Galectin-3 has been shown to participate in M2-polarization and to
promote extensive ﬁbrosis [31–33]. This is believed to be due to the
ability of strengthen TGF-β signaling associated with tissue remodeling
[34]. Elevated galectin-3 plasma levels have been shown in end stage
renal disease [35].
Since growth factors belonging to the TGF-β superfamily play an
essential role in renal ﬁbrosis and macrophages are suggested to be
among the main producers of TGF-β [21], we evaluated whether
TGF-β production and galectin-3 expression in macrophage subsets
are increased in the kidney of the db/db and STZ diabetic nephropathy
mouse models. The STZ model shows signiﬁcant β-cell deﬁciency,
however it lacks the autoimmune component noted in human T1D
nephropathy, while the db/db model lacking a functional leptin-
receptor shows rapid weight gain, obesity and pronounced insulin
resistance. Further, we addressed if a certainmacrophage population
was responsible for the galectin-3 expression. Finally, we evaluated the
treatment effect of the ﬁrst line therapy – the ACE inhibitor enalapril,
which is administrated to diabetic nephropathy patients – on the
inﬂammatory compartment in the diabetic kidney.
Taken together, a proﬁle characterized by elevated expression
of galectin-3 and TGF-β in concert with the reduced presence of
M1-macrophages, B and T cells was demonstrated in the diabetic
kidney when the albuminuria levels were signiﬁcantly increased.
Enalapril treatment promoted a longer lived M1-like macrophagephenotype and local increase in the number of CD4+ T cells, partial
down-regulation of galectin-3, but no modulation of TGF-β expression.
These data suggest that the observed effect of ACE inhibition on
albuminuria might be due to partial restoration of the M1-like
phenotype of macrophages. Speciﬁc treatment regimens targeting
the balance of M1–M2 macrophages might provide novel therapeutic
openings in the treatment of diabetic nephropathy.
2. Materials and methods
2.1. Animals
Male db/db mice 6–8 weeks of age were purchased from Charles
River, Belgium and fed Altromin 1324 food pellets ad libitum. From
weeks 8–10 of age, one group ofmicewere given the enalapril treatment
(5 mg/kg added to food pellets by Altromin) in the standard Altromin
1324 food pellets ad libitumuntil 20–22 weeks of age when the
experiment was terminated. 129SV mice were purchased from Charles
River, Germany at 8 weeks of age. At 9 weeks of age the mice were
given streptozotocin (STZ) injections IP at a dose of 125 μg/kg on days
1 and 4. In two weeks post STZ treatment, blood glucose measurements
were conducted andmice showing elevated blood glucose above 16mM
were included in the experiment. In six weeks post the initial STZ
injection, the enalapril treatment (5 mg/kg added to food pellets by
Altromin) was started which lasted until termination 12 weeks
later. All in vivo experiments were performed at Phenos GmbH,
Hannover, Germany under ethical approval from the national regulatory
authorities that included treatment of diabetic animals with therapeutic
agents like the ACE inhibitors.
2.2. Blood glucose measurement and HbA1c
Evaluation of blood glucose levels was performed onceweekly using
a Contour glucometer from Bayer, Leverkusen, Germany as indicated by
the manufacturer. HbA1c% measurements were performed every four
weeks by an Olympus AU400 using standard reagents.
2.3. Measurement of albuminuria
Albuminuria was determined at the start of experiment (db/dbmice
at 10weeks of age and STZmice 6-weeks post STZ treatment) as baseline
value, mid-point 6-weeks into the experiment and terminal at 12-weeks
post start of experiment.
For urine collection, the mice were placed in metabolic cages for
15–16 h overnight. During the stay in the metabolic cages the
animals had free access to food and water, but did not have bedding
or enrichment. Albumin levels were measured in the urine samples
using the Mouse Albumin ELISA Kit (Bethyl Lab, Hamburg, Germany)
according to the manufacturer's instructions, and converted to 24 h
urinary albumin excretion by dividing the exact number of hours in
the metabolic cages and multiplying by 24.
2.4. Preparation of single cell suspension from mouse kidney
Kidneys were cut into small pieces and digested in media (RPMI
with 5% serum) supplemented with 2 mg/ml collagenase II (Gibco)
and 50 U/ml DNase (Sigma, St. Louis, MO, USA) by incubating for
40min at 37 °C on a roller mixer. To release glomeruli from interstitium
the samples were pipetted up and down before passing through a
100 μm cell strainer (BD Biosciences). The cell suspension was washed
and erythrocytes were lysed with cell lysis buffer. To digest glomeruli,
the preparation was further incubated in media supplemented with
0.5 mg/ml collagenase type II, 50 mg/ml dispase II (Sigma), 50 U/ml
DNase and 0.075% trypsin (Gibco). The cells obtained were washed,
resuspended in 1× HBSS without salts with 2 mM EDTA and incubated
for 10 min on ice. In order to disrupt tubular structures the suspension
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passed through a 40 μm cell strainer (BD).
2.5. Flow cytometry analysis
Flow cytometric analysis was performed according to standard
procedures. Brieﬂy, cells were ﬁrst blocked for unspeciﬁc binding
with anti-CD16/CD32 (BD Biosciences), followed by surface staining
of CD11c (BD Biosciences), F4/80 (BioLegend), CD45 (eBioscience),
B220 (BD Horizon), CD4 (BioLegend), CD8 (BD Biosciences). Cells
were then ﬁxed and permeabilized using the Cytoﬁx/Cytoperm kit
(BD Biosciences), according to the manufacturer's description and
then intracellularly stained for CD68, CD206 (both AbD Serotec),
galectin-3 (BioLegend) and TGF-β (BioLegend). Samples were
acquired on a FACS LSRFortessa, equippedwith blue, red and violet lasers,
followed by data analysis using FACSDiva software (BD Biosciences).
2.6. Determination of local kidney cytokine production
Protein homogenatewas generated from frozen kidney tissue. Brieﬂy,
kidney was placed in a tissue lyser with lysis buffer [aprotinin (Sigma),
leupeptin (Tocris) and pepstatin (Tocris)] followed by addition of
Triton-X100 (Sigma) and ﬁnally centrifuged. Protein concentration was
determined and equal amounts of protein were added to Proteome
ProﬁlerMouse Angiogenesis Array Kit (R&D System). Relative expression
of cytokines within the kidney tissue was expressed as signal detected
over background signal for each protein analyzed.
2.7. Data analysis
Data were analyzed by 1-way ANOVA and Dunnett's post hoc test
with the diabetic vehicle treated group as control. The level of signiﬁcance
was set at p b 0.05. All analyses were done using GraphPad Prism version
6.02.
3. Results
3.1. Development of diabetic nephropathy
To generate translational knowledge, the effect of enalapril was
determined in an advanced STZ mouse model (mimicking T1D DN;
hyperglycemia and with diminished β-cell mass) and the db/db
mouse model (mimicking T2D DN; hyperphagic, obese, hyperglycemic
and dyslipidemia) at a stage that resembles the human situation when
enalapril treatment is initiated (Fig. 1A, B). Both models had been
hyperglycemic for 4–5weeks at the initiation of the enalapril treatment
as indicated by the ﬁgure (Fig. 1A, B).
Both the db/db and the STZ-treated mice showed pronounced
diabetes at the start of the experiment measured as elevated
HbA1c% (Fig. 1C, E). The development of diabetes showed a progression
during the experiment reaching 2.5 to 1.3-fold enhanced blood glucose
levels at termination respectively (Fig. 1C, E). Treatment with enalapril
had no effect on diabetes measured as HbA1c compared to untreated
diabetic animals (Fig. 1C, E). The db/dbmice had signiﬁcantly enhanced
albuminuria already at the start of the experiment with levels 5-fold
higher than age-matched healthy db/+ mice (Fig. 1D). Interestingly,
the db/db mice showed a 1.5-fold increase of albuminuria after 6
weeks, which then was reduced to levels below the starting value at
termination of the experiment (Fig. 1D). Treatment with enalapril
signiﬁcantly reduced the albuminuria after 6-weeks of treatment
(Fig. 1D). At termination of the experiment, the albuminuria levels
in the enalapril treated group were at the same level as after 6-weeks
treatment. However, as the untreated vehicle group showed a spontane-
ous reduction of albuminuria levels, there was no signiﬁcant treatment
effect of enalapril (Fig. 1D). At start of the STZ model experiment
(6-weeks post STZ treatment), the albuminuria levels were thesame in the STZ group as in the non-STZ mice (Fig. 1F). Similarly to
the db/dbmice, the STZmice showed a transient increase of albuminuria
with signiﬁcant 2.5-fold increased levels at 6-weeks, which then de-
clined to 1.5-fold the starting values at termination of the experiment
(Fig. 1F). Treatment with enalapril signiﬁcantly reduced the increase of
albuminuria after 6 weeks of treatment (Fig. 1F). However, due to the
spontaneous reduction of albuminuria at termination of the experiment,
no signiﬁcant effect of albuminuria was noted with enalapril after
12 weeks of treatment. Also in this model, the albuminuria level
in the enalapril treated group was stable from 6–12 weeks of
treatment.
These data show that in both T1D and T2Dmodels of DN, a transient
increase of albuminuria was noted with peak level of albuminuria at
16-weeks of age in db/db mice and 21-weeks of age in STZ treated
animals. Enalapril treatment in mice experiencing hyperglycemia
for a similar period showed no effect on development of diabetes,
but signiﬁcantly delayed the progression of albuminuria in both
models.
3.2. Enalapril treatment restores leukocyte numbers in the diabetic kidney
With the presence of DN established in both the T1D and T2D DN
models, the effect of enalapril on the local inﬂammatory milieu was
determined at termination of the experiment measured as the total
number of leukocytes in the db/db and STZ kidney compared to their
healthy control group.
The previously described immune-compromised db/db mice
showed a signiﬁcant reduction in the total number of CD45+ leukocytes
compared to healthy db/+ littermates (Fig. 2A). Treatmentwith enalapril
signiﬁcantly increased the number of leukocytes present in the kidney to
levels detected in the healthy db/+ littermates (Fig. 2A). Although
reduced, there was no statistically signiﬁcant reduction of leukocytes in
the STZ treated mice (Fig. 2B). However, as noted in the db/db mice,
enalapril treatment resulted in a signiﬁcant increase in the number of
leukocytes at termination of the experiment (Fig. 2B). Of interest, the
total number of leukocytes regardless diabetes or diabetic nephropathy
was 5-fold lower in the db/+and db/db compared to the 129SV and STZ
129SV mice (Fig. 2A, B).
Taken together, in both T1D and T2D advanced pre-clinical DN a
reduction of leukocytes was observed compared to healthy control
mice. Enalapril treatment prevented the loss of leukocytes in both
models and with STZ treatment the levels were even higher than in
non-diabetic control mice.
3.3. Enalapril treatment results in increase of kidney CD68+F/80+
macrophages in db/db mice
Studies have shown a correlation between increased number of
kidneymacrophages and the severity of DN in patients [35–38]. Further,
macrophages have been shown to be the ﬁrst immune cells to enter the
diabetic kidney [21,39,40]. Given the observed reduction of leukocytes
in the advanced diabetic kidney, particularly in the db/db mice and
the increase in numbers after enalapril treatment, the number of
macrophages was determined (Fig. 3A–C).
In the db/db T2D model, the total numbers of both CD68+F4/80+
and CD68+F4/80−macrophages were signiﬁcantly reduced compared
to healthy littermates (Fig. 3D, E). Enalapril treatment counteracted
the loss of CD68+F4/80+ macrophages, while it had no effect on the
CD68+F4/80− macrophages (Fig. 3D, E). Interestingly, the number of
macrophages in STZ treated mice was not signiﬁcantly modulated
compared to healthy control mice. Although a small trend to increase
in both macrophage subsets was noted after enalapril treatment, no
signiﬁcant changes were demonstrated in the STZ mice after treatment
(Fig. 3F, G).
Taken together, the results showed that enalapril treatment
counteracted the loss of CD68+F4/80+ macrophages, but not of
Fig. 1. Layout of the diabetic nephropathymodels used in the study (A, B). HbA1c (C, E) and albuminuria (D, F) in db/db (C, E) and STZ (D, F) mice before and after 6 or 12weeks of treat-
ment with ACE inhibitor and their respective controls. ****p b 0.0001; ***p b 0.001; **p b 0.01; *p b 0.05.
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statistical effect was observed on macrophage numbers in the T1D
STZ model.
3.4. Enalapril promotes polarization of the macrophages towards a M1-like
phenotype
To further evaluate if enalapril modulates not only the number of
macrophages, but also the functional stage of the kidney derived
macrophages, expression levels of markers associated with M1 and
M2 polarization were determined (Fig. 4).
Kidney-derived macrophages from advanced DN in the db/db mice
showed a signiﬁcant reduction of the M1-associated CD11c marker
both in the CD68+F4/80+ and CD68+F4/80− subsets compared to
healthy db/+ littermates (Fig. 5A, B). Treatment with enalapril signiﬁ-
cantly increased the expression of CD11c on both subsets, but particularlyon CD68+F4/80−macrophages in the db/dbmice compared to untreated
mice (Fig. 5A, B). In the STZ mice, a highly signiﬁcant reduction of CD11c
was noted on the CD68+F4/80+ macrophages, while the CD68+F4/80−
macrophages showed only a partial non-signiﬁcant reduction (Fig. 5C,
D). In contrast to the db/db model, no restoration of CD11c expression
level was noted on CD68+F4/80+ macrophages in the STZ mice after
enalapril treatment (Fig. 5C). However, the expression of CD11c on
CD68+F4/80− cells trended to be enhanced after enalapril treatment in
the STZ mice compared to untreated STZ mice (Fig. 5D). A moderate
reduction of the M2-associated marker CD206 was demonstrated in the
CD68+F4/80+ macrophages in the db/db mice, whereas no modulation
was noted in the CD68+F4/80− macrophages (Fig. 5E, F). Enalapril
treatment did not modulate the expression of CD206 in the db/db
mice (Fig. 5E, F). A non-signiﬁcant pattern suggesting an increase of
CD206 expression on CD68+F4/80+ macrophages was noted in the
STZ mice, while no modulation was noted in the CD68+F4/80−
Fig. 2. Total number of CD45+ cells in (A) db/db and (B) STZ kidneys with and without
treatment with ACE inhibitor and their respective controls (mean ± SEM; n = 6).
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signiﬁcant trend to further increased CD206 expression compared to
untreated STZ mice in the CD68+F4/80+ macrophages, resulting in a
highly signiﬁcantly enhanced expression compared to healthy control
mice (Fig. 5G).
Taken together, these data revealed that the advanced diabetic
nephropathy in pre-clinical mouse models is associated with a highly
signiﬁcant reduction of the classical M1-like macrophage phenotype
while the M2 marker CD206 is only moderately modulated locally in
the kidney. Interestingly, enalapril treatment promotes a polarization
of the kidney macrophages towards an M1-like phenotype in a subset
of macrophages in both db/db and STZ mice. Thus, ACE inhibition
appears to inﬂuence the shift in M1/M2 polarization in macrophages
overall favoring the classically activated M1-like pro-inﬂammatory
phenotype of macrophages (CD11c), which is reduced with disease
progression in mouse diabetic nephropathy while no signiﬁcant
modulation of the alternatively activated CD206 macrophages was
noted.
3.5. Enalapril treatment partly counteracts polarization of macrophages
into a galectin-3+ phenotype
Galectin-3 is expressed by a subset of macrophages which has been
shown to be a key driver of ﬁbrosis in several chronic inﬂammatory
disorders often associated with M2-like polarization [32,33,36]. As
enalapril treatment in late pre-clinical diabetic nephropathy inﬂuenced
the polarization of macrophages into a M1-like phenotype, the
galectin-3 expression level on the kidney macrophages was determined
as a measurement of a ﬁbrotic macrophage signature (Fig. 4).
No modulation of galectin-3 expression was noted in CD68+F4/80+
macrophages in either the T2D db/db or in the T2D STZ model (Fig. 6A,
C). In sharp contrast, a 2-fold increased galectin-3 expression level was
noted in both the db/db and in the STZmodel on CD68+F4/80−macro-
phages (Fig. 6B, D). Treatment with enalapril in the db/db model did
show a signiﬁcant 50% reduction of the expression compared to theuntreated db/db mice (Fig. 6B). A similar, but less pronounced
non-signiﬁcant 40% reduction of galectin-3 expression was noted on
the CD68+F4/80− macrophages in STZ-treated mice after enalapril
administration (Fig. 6D). Of note, the galectin-3 expression in the db/
dbmicewas signiﬁcantly higher compared to the STZmice (Fig. 6A–D).
These data show that enalapril partly counteracts the elevation of
galectin-3 expression in the kidney derived CD68+F4/80−macrophages
in both models suggesting that ACE inhibition might provide beneﬁcial
effect on the ﬁbrotic signature in M2-like macrophages.3.6. Enalapril failed to modulate the expression of TGF-β in diabetic kidney
macrophages
The pro-ﬁbrotic property of galectin-3 is partly due to its ability to
strengthen TGF-β signaling by stabilizing the TGF-β receptor and
hence to promote myoﬁbroblast differentiation [36]. As TGF-β has
been shown to drive ﬁbrosis in diabetic nephropathy and expression
of galectin-3 was modulated in the model, the intrinsic TGF-β produc-
tion in kidney macrophages was determined after enalapril treatment
(Fig. 4).
Interestingly, neither the CD68+/F4/80+ nor the CD68+F4/80−
macrophages showed elevated levels of TGF-βI in the db/db mice
(Fig. 6E, F). In contrast, the STZ treated CD68+F4/80+ macrophages
showed a highly signiﬁcant upregulation of TGF-β, while the
CD68+F4/80− only showed a trend towards upregulation (Fig. 6G,
H). Enalapril treatment in both the db/db and the STZ model had
no modulatory effect on the expression of TGF-β in the macrophages
(Fig. 6E–H).
Taken together, thedata demonstrate that intrinsic TGF-β expression
in db/db kidneymacrophages is not elevated compared to healthymice,
while STZ kidney derived macrophages showed a signiﬁcantly higher
expression level. Enalapril treatment is ineffective in modulating
the intrinsic capacity to express TGF-β in the diabetic kidney
macrophages.3.7. Signiﬁcant lymphocyte defects in the diabetic kidney are partly
counteracted by enalapril treatment
A growing understanding of lymphocytes in diabetic nephropathy has
been generated the last few years [37,38]. To address whether enalapril
treatment affected the kidney associated trafﬁcking of lymphocytes, B
cell, CD4+ and CD8+ T cell numbers were determined.
In the db/db model, the overall number of lymphocytes was
reduced. Particularly, the number of B cells in the diabetic db/db kidney
was highly signiﬁcantly reduced compared to healthy db/+ mice
(Fig. 7A). Moreover, as in peripheral tissue e.g. spleen, the db/db mice
showed a signiﬁcant reduction of CD4+ T cells in the diabetic kidney,
while a non-signiﬁcant reduction of CD8+ T cells was noted (Fig. 7C,
E). Similarly, a general reduction of lymphocytes was noted in the
advanced STZdiabetic kidney. Althoughnot signiﬁcant, a 50% in reduction
of absolute count of B cells was noted in the STZ diabetic animals
compared to healthy non-STZ mice, while no modulation of T cell
absolute numbers was noted (Fig. 7B, D, F). Treatment with enalapril
had no effect on the B cell absolute count in neither of the models
(Fig. 9A, B). In sharp contrast, the T cells were signiﬁcantly affected
by enalapril treatment. In db/dbmice normalization to the levels recorded
in healthy non-diabetic db/+micewas noted (Fig. 7C, E). In the STZmice,
both the CD4+ and the CD8+ T cells showed pronounced expansion to
levels clearly above the levels noted in healthy littermates (Fig. 7D, F).
These data show that the diabetic kidney is markedly lymphopenic
compared to the healthy kidney. The reduction of B cells cannot be
counteracted by ACE inhibition. In contrast, the T cell compartment
and particularly the CD4+ T cells responded to enalapril treatment by
an increased accumulation in the kidney.
Fig. 3. Gating strategy to identify subsets of macrophages in the kidney (A–C). Total number of CD68+F4/80+ vs. CD68+F4/80−macrophages in (D, E) db/db and (F, G) STZ kidneys with
and without treatment with ACE inhibitor and their respective controls (mean ± SEM; n = 6).
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which is unaffected by enalapril
Local production of chemokines, cytokines and growth factors are
known to modulate the presence of leukocytes in inﬂamed tissues [18,39]. To address if enalapril treatmentmodulated the chemokine signature
in the diabetic kidney, proteins in whole kidney homogenates were
analyzed.
Several cytokine and chemokines were modulated in the diabetic
db/db and STZ kidneys. However, only CXCL16 was signiﬁcantly
Fig. 4. Representative mean ﬂuorescence intensity (MFI) histograms for CD68+F4/80+ CD11c (A, B), CD206 (C, D), TGFβ1 (G, H) and CD68+F4/80− Galectin-3 (E, F) comparing healthy
db+ versus diabetic db/db kidneys (A, C, E, G) and healthy non-STZ and diabetic STZ-induced kidneys (B, D, F, H).
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non-diabetic tissue (Fig. 8A, B). Notably, the levels of KC and fractalkine
were both markedly higher in the db/db model than in the STZ model
(Fig. 8C, D). In the db/db kidney, a non-signiﬁcant reduction of KC was
noted in the diabetic kidney compared to the healthy tissue (Fig. 8C).
Of importance, treatment with enalapril signiﬁcantly reduced the
diabetes enhanced CXCL16 levels in the STZ model, but failed to do so
in the db/db model (Fig. 8A, B). In contrast, enalapril treatment in the
STZ model signiﬁcantly enhanced the levels of both KC and fractalkine,
while no treatment effect was noted in the db/db model (Fig. 8C–F).
Taken together, the data shows that the expression of cytokines and
chemokines is modulated in diabetic nephropathy. Moreover, enalapril
modulates the expression pattern but only in the STZ model.
4. Discussion
Prolonged exposure to elevated glucose concentrations or frequent
rapid ﬂuctuations causes signiﬁcant stress to the kidney [40]. Over
time this leads to structural changes in the kidney that are manifested
in human subjects as loss of podocytes, mesangial cell expansion,
glomerulosclerosis and interstitial ﬁbrosis [40]. With the change in life
style during the last decades, the number of diabetes patients has
increased signiﬁcantly and with that the number of patients suffering
from the diabetic complication diabetic nephropathy [1]. Although
several lines of therapies exist including the ACE inhibitors, the efﬁcacy
of them is only partial and may delay, but never revert the decline in
kidney function [3]. This leads to an increased number of patients
waiting for kidney transplantation associated with huge cost burdens
for the society.
Several animal models of DN have together provided valuable
information regarding pathophysiology, progression, implicated
genes and proposed new therapeutic strategies [13]. The common
for all pre-clinical animal models is that they fairly well mimic the
early changes in the human disease, but fail to develop the later
stages [13]. Despite this limitation, they have been instrumental for
the emerging concept that DN indeed contains local modulation ofthe inﬂammatory signature [11,14,41,42]. In our models, we prolonged
the standard time for diabetic nephropathy mouse models with an
additional 4–7 weeks to further allow tissue modulations to take
place. In these prolonged models, we unexpectedly noted a signiﬁcant
reduction of total leukocytes in the db/dbmodel and a trend to reduction
in the STZ model. This reduction in leukocytes was mainly due to a loss
of macrophages and CD4+ T cells in the db/db mice, B cells in both the
db/db and the STZ mice and CD8+ T cells in the STZ mice. Although
surprising, the reduction ofmacrophages observed in the diabetic kidney
is consistent with previous studies showing that the differentiation/
polarization state of the macrophages was changed rather than the
number of cells in the diabetic kidney [24]. These observations are in
line with our previous observation that the initiation of diabetes is
strongly associated with a M1-like phenotype which gradually
transforms into aM2-like phenotype in late stage diabetes in the systemic
compartment [22]. Polarization and differentiation of macrophages are
difﬁcult to address since macrophages rapidly undergo re-polarization
depending on local signals [18]. Several markers have been used to
identify M1-like and M2-like macrophages but only rarely can a clear
M1 or M2 macrophage be described in vivo. It is however well accepted,
and was recently described in a pre-clinical diabetic model, that among
other markers, CD11c is upregulated on M1-like macrophages, whereas
CD206 (the mannose receptor) is expressed on M2-like macrophages
[19,20,22]. Interestingly, the macrophages present in the advanced
db/db and STZ kidneys had highly signiﬁcantly reduced expression
of the M1 marker CD11c. Macrophages expressing CD11c have
been shown to have a classical pro-inﬂammatory cytokine signature
associated with elevated production capacity of IFN-γ, TNF-α and IL-1β
[18,20,43]. Moreover, these cells are considered highly professional APC
and are associated with elevated levels of MHC-II and several co-
stimulatorymolecules needed to promote strong lymphocyte responses
[43]. We recently described that the systemic expression of these pro-
inﬂammatory cytokines in the plasma is similar in healthy control
animals and in late stage disease in the db/db model, whereas in the
initiation phase the levels are increased [22]. Herein, we extend this
observation, by describing that the local kidney levels of these cytokines
Fig. 5.Mean ﬂuorescence intensity (MFI) showing CD11c (A–D) and CD206 (E–H) expression levels on CD68+F4/80+ vs. CD68+F4/80−macrophages in db/db (A, B, E, F) and STZ (C, D, G,
H) kidneys with and without treatment with ACE inhibitor and their respective controls (mean ± SEM; n = 6).
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the macrophages into a state with reduced capacity to produce pro-
inﬂammatory cytokines associated with M1-like phenotype. Interest-
ingly, in the db/dbmodel, the kidney derivedmacrophages also showed
the reduced expression of the M2-associated marker CD206, while a
trend towards elevated levels were noted in the STZ macrophages. Li
et al. recently showed that polarization towards alternatively activated
M2-like phenotype in a high-fat diet (HFD) induced model wasdependent on iNKT cellular activity [44]. In absence of these cells in
the Cd1−/−mouse, HFD failed to induce these M2-like cells resulting
in severe hyperglycemia and insulin tolerance [44]. db/db mice
are known to be highly insulin resistant and display accelerated
hyperglycemia [45]. In addition, these mice show a defect development
of iNKT cells associatedwith signiﬁcantly reduced numbers in peripheral
tissues including the adipose tissue [46]. In contrast, STZ treated mice
showed normal development of iNKT, but the cells do show reduced
Fig. 6.Mean ﬂuorescence intensity (MFI) showing galectin-3 (A–D) and TGFβ (E–H) expression levels on CD68+F4/80+ vs. CD68+F4/80−macrophages in db/db (A, B, E, F) and STZ (C, D,
G, H) kidneys with and without treatment with ACE inhibitor and their respective controls (mean ± SEM; n = 6).
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production of Th1 cytokines like IFNγ [47]. Hence the reduction of
macrophages in the db/db mice and consequent partial loss of M2-like
phenotype in the db/db mice could be dependent on the selective loss
of iNKT cells in that strain, while the partial induction and long lived
macrophage population in the STZ mice showing a mixed M1/M2
polarization could relate to the altered function of the cross-talk with
the iNKT.Late stage DN in humans is associated with excessive remodeling
and ﬁbrotic events [2]. M2 macrophages are well described to promote
remodeling activity and ﬁbrosis in other conditions and in vitro [18,20].
Our data with a relative shift from aM1-like towards M2-like macro-
phages suggests that the local leukocytes in the diabetic kidney
resemble the phenotype known to initiate ﬁbrotic events. This was
further strengthened by the increased expression of galectin-3 on
macrophages in both models. Galectin-3, a β-galactoside-binding
Fig. 7. Total number of B cells (A, B), CD4+ T cells (D, E) and CD8+ T cells (G, H) in db/db (A, C, E) and STZ (B, D, F) kidneys, respectively,with andwithout treatmentwith ACE inhibitor and
their respective controls (mean ± SEM; n = 6).
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of DN in man were galectin-3-positive macrophage inﬁltration in
the glomeruli in patients with DN is correlated with progression of the
disease [48]. Once there, the macrophage derived galectin-3 is
considered to participate strongly in the immunological promotion
of renal ﬁbrosis [33]. Pharmaceutical intervention or knock-down
of galectin-3 has been shown to render mice less susceptible to STZ
induced T1D [48]. However, galectin-3 ablation in a HFD mouse
model accelerated adipose tissue and pancreatic islet inﬂammation
probably by favoring development of excessive M1-like macrophages
[49]. Furthermore, Pugliese et al. showed that the knock-down of
galectin-3 in STZ treated C57Bl/6 mice accelerated diabetes-associated
kidney damage rather than providing protection [50]. C57Bl/6 mice
are well known to be resistant to diabetic kidney damage, while it is a
good strain to induce classical M1 responses [51]. The dose of STZ
administrated the frequency of administrations and the length of the
model modulates the induction and severity of the disease and could
be an explanation for the conﬂicting results [51]. Still, a consistentfeature of galectin-3 is its upregulation in macrophages in chronic
inﬂammation or ﬁbrotic conditions. Galectin-3 is a plieotropic molecule
regulatingmacrophage polarization fromM1-like to themore proﬁbrotic
M2-like phenotype and strengthening TGFβR signaling by retaining cell
surface expression of TGF-β receptors [29,52–55]. In both the db/db and
the STZ model, a pronounced expression of TGF-β receptors was noted
which might be stabilized due to the upregulated galectin-3 (data not
shown). TGF-β production is elevated in peripheral db/db macrophages
[22] and herein, a similar increase of TGF-β in kidney derived
macrophages in STZ, but not db/db, was noted. Marked increased
TGF-β signaling manifested as enhanced pSMAD2/3 has been
shown in both db/db and in STZ DN mice models [34,55]. This
signaling has been demonstrated to participate to the mesangial
cell expansion and the initial ﬁbrotic events occurring in the mice
[35]. It is tempting to speculate that the enhanced galectin-3 levels
noted together with the presence of TGF-β-TGF-β receptors contribute
to the enhanced pSMAD2/3 expression leading to the early ﬁbrotic
events.
Fig. 8. Expression of cytokines in the diabetic kidney. Relative expression of CXCL16 (A, B), KC (C, D) and fractalkine (E, F) in db/db (A, C, E) and STZ (B, D, F) kidneys, respectively, with or
without treatment with ACE inhibitor. Four individual kidneys were evaluated in each condition (mean ± SEM).
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the long term beneﬁt for the patient is only transient and moderate [56].
ACE inhibition is clinically associated with reduction of urinary MCP-1
levels and in pre-clinical models of remnant kidney disease it has been
shown to prevent local proliferation of macrophages and myoﬁbroblasts
in the kidney [57]. However, Albuquerque et al. showed that enalapril
treatment potently increases the number of CD4+ T cells in the spleen
together with the increasing production of IL-2 and IL-10 [58]. Our
observation that the overall kidney associated leukocyte number,
speciﬁcally the CD4+/CD8+ T cells, is increased after enalapril treatment
in both db/db and STZ treated mice demonstrates that the angiotensin II
blockade overall seems to favor proliferation or attraction of lympho-
cytes speciﬁcally in advanced disease. Furthermore, enalapril treatment
modulated the kidney macrophage polarization towards a M1-like
phenotype associated with enhanced CD11c, unchanged CD206 and
TGF-β expression and reduced galectin-3 expression. This multi-
facilitated picture of macrophage polarization stresses the complexity
ofmacrophage plasticity and polarization particularly under pathological
conditions in vivo [59]. Interestingly, IL-4 and IL-13 stimulation in human
macrophages, which promotes M2 polarization, increases ACE expres-
sion while LPS and IFN-γ stimulation, which promotes M1 polarization
reduce ACE expression in macrophages [60]. Further, Ito et al. elegantlydemonstrated that these Th2-associated cytokines (IL-4, IL-13 and
PDE2) not only promote the development of M2-macrophages, but also
were essential for the ﬁbrotic responses in UUO kidney models in mice
[61]. Hence ACE inhibition in vivo may counteract production of
Th2/M2 associated cytokines thereby promoting a sustained M1
macrophage population. Since enalapril treatment promotes a growing
T cell population with a shift in the cytokine signature towards IL-10,
with reduced capacity to produce IL-4 and IL-13, it appears like a shift
towards a phenotype resembling a T regulatory cell population [62].
This induction of regulatory T cells by ACE inhibitors has previously
been shown in autoimmune diseases like multiple sclerosis [62].
Current work in our laboratory is addressing whether enalapril
treatment indeed causes a similar development in the diabetic kidney.
However, the clinical efﬁcacy of ACE inhibition is moderate [3], similar
to the pre-clinical transient beneﬁcial effect observed in this study. This
limited effect might be due to the promotion of long-lived M1-like
macrophages in diabetic kidney which could contribute to the disease
progression despite the polarization of T cells towards a regulatory
phenotype.
Taken together, pre-clinical DN is associated with a reduction of
immune cells, particularly B and T cells, together with a polarization
of the macrophages towards a M2-like phenotype associated with a
41H. Cucak et al. / International Immunopharmacology 25 (2015) 30–42signiﬁcant induction of galectin-3 expression. Enalapril treatment
shows a transient efﬁcacy by reducing the albuminuria together with
an expansion of the T cells, and by re-polarizing the macrophages
towards a M1-like state without modulating the TGF-β expression.
This modulation of the local immunity might provide a mechanistical
explanation as to why ACE inhibition provides moderate efﬁcacy in
man. In conclusion, the data presented provides a ﬁrst insight to
which inﬂammatory signatures that still remains after the ﬁrst-line
therapy of DN and hence proposes ideas for development of novel
therapeutic approaches in the disease.
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